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Poster Session-I 63p 5 0.27). Cause of death was relapse 23%, aGVHD 2%, cGVHD
1%, infection 2%, MSOF/ ARDS 3% and other 2%. In conclusion:
the use of t-Bu/Flu in AML patients, with a daily AUC targeted at
5300610% is a tolerable regimen with lowNRM. It is also well tol-
erated regardless of age. Patients in a first CR, even those with URC,
have very good outcomes. Relapse is still an issue in these AML pa-
tients and post transplant therapy should be considered, particularly
for patients not in remission at the time of transplant. Currently we
are assessing the maximum tolerated AUC of Bu in an ongoing trial.168
SEQUENTIAL THERAPY WITH NONABLATIVE ALLOGENEIC STEM CELL
TRANSPLANTATION, POST TRANSPLANT IMATINIB AND DONOR LYM-
PHOCYTE INFUSION FOR CHRONIC MYELOID LEUKEMIA
Champlin, R.E., de Lima, M., Giralt, S., Kebriaei, P., Anderlini, P.,
Qazilbash, M., Hosing, C., Shpall, E., Fisher, T., Gabriela, R. MD An-
derson Cancer Center, Houston, TX
Allogeneic stem cell transplantation (ASCT) is a potentially cura-
tive therapy for patients(pts) with CML. Its use has declined because
of the favorable results of tyrosine kinase inhibitors (TKIs), and con-
cerns regarding toxicity andGVHD.The efficacy of ASCT is largely
due to the immune graft-vs.-leukemia effect. Nonmyeloablative con-
ditioning has reduced toxicity, and post transplant treatment with
imatinib and donor lymphocyte infusions can produce durable mo-
lecular complete remissions in pts with residual disease.We prospec-
tively studied use of a reduced intensity preparative regimen
involving fludarabine, busulfan and Thymoglobulin followed by
ASCT from an HLA identical or one antigen mismatched related
or unrelated donor. Pts who do not achieve molecular CR (mCR) af-
ter 3 mo received TKI treatment. Those without mCR after an ad-
ditional 3 mo received escalating doses of donor lymphocyte
infusion (DLI). 42 pts, median age 42 yrs (range 14–69) were en-
tered. All were previously treated with imatinib, but with detectable
disease. 20 had early disease (chronic phase or isolated clonal evolu-
tion) and 22 had advanced CML (prior accelerated or blast phase). 4
early and 9 advanced pts had a cytogenetic CR (CyCR) at the time of
transplant. The regimen was well tolerated without life-threatening
toxicity except for one pt with reversible transplant related microan-
gioapathy. Two pts had graft failure, one required a second trans-
plant and the other had autologous recovery with Ph-
hematopoiesis. Only one pt died within 100 days post transplant.
At 3 months, all of the chronic phase pts and 21 of the 18 advanced
pts achieved CyCR and 7 early and 5 advanced pts achieved a mCR.
22 pts received treatment with TKIs post transplant; mCR was
achieved in 7 of the 9 early pts and 2 of 13 advanced pts. 16 pts sub-
sequently received DLI; 2 of 2 pts with early disease achieved mCR
with one other pt too early to evaluate; 2 of 13 advanced pts have
a mCR. 31 pts are alive. This includes 18 of 20 (90%) transplanted
with early disease, (all in cCyR 13 in cMR) and 13 of the 22 (59%)
with advanced disease (7 in cCyR and 9 in cMR). This sequential
strategy of nonmyeloablative ASCT, post transplant TKIs, and
DLI is associated with a low treatment relatedmortality and deserves
further study to produce durable mCR in patients with a suboptimal
response to imatinib. Most favorable results were achieved in pts
without overt transformation.169
REDUCED INTENSITY CONDITIONING (RIC) REGIMEN FOLLOWEDBY AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN
ADULT PATIENTS (PTS) WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Silva L., De Padua1, Saliba, R.1, Giralt, S.1, Hosing, C.1, Khouri, I.1,
Popat, U.1, Qazilbash, M.1, Shpall, E.1, Thomas, D.2, Kantarjian, H.2,
Champlin, R.1, Kebriaei, P.1 1 The University of Texas MD Anderson
Cancer Center, Houston, TX; 2 The University of Texas MD Anderson
Cancer Center, Houston, TX
Background:RIC regimens are less myelosuppressive, but still al-
low for successful engraftment with acceptable treatment-related
mortality (TRM) in frail pts who otherwise would not be suitable
candidates for HSCT. This is particularly relevant in ALL, since
pts often sustain toxicity from dose-intense regimens, or may bediagnosed in advanced age. The antitumor effect of this approach
is not well-established in ALL.
Methods: We evaluated 30 ALL pts (19 M/11 F) treated from
1996 to 2008 with fludarabine 120 mg/m2, melphalan 140 mg/m2
and unmanipulated stem cells. GVHD prophylaxis consisted of
tacrolimus and mini-methotrexate. Anti-thymocyte-globulin was
added to matched unrelated pts.
Results: Median age was 44 years (range 23–64). ECOG status at
time of HSCT was 0 (n 5 16), 1 (n 5 10) or 2 (n 5 4) with median
co-morbidity score of 3 (range 0–7) by Charlson Comorbidity Index.
24 pts had B-lineage and 6 had T-lineage disease. Cytogenetic data
were available for 26 pts; 19 had high-risk cytogenetics, including
9 with Ph1 disease. Disease stage at time of study entry was CR1
(n 5 5), $CR1 (n 5 12), or primary or refractory relapse (n 5 13),
with median 2 prior chemotherapy regimens (range 1–4); five pts
had a prior allogeneic HSCT. Donor type was matched related
(n 5 13) or matched unrelated (n 5 17) and stem cell source was
bone marrow (n5 14) or peripheral blood (n5 16). The median to-
tal nucleated cell dose and CD341 cell dose were 3.80  108 cells
(range 0.68 – 17.16) and 4.15 106 cells (range 1.78 – 12.03), respec-
tively. Median time to ANC 0.5  109/L was 13 days (range 10–24).
Median time to platelet count 20 109/L was 18 days (range 10–57).
Eight pts were alive at a median follow up of 12 months fromHSCT
(range 3–59). OS and DFS were 32% and 29%, respectively, at 1
year. Of note, only 1 among 5 pts in CR1 had disease progression,
compared to 8 among 13 with refractory disease at time of HSCT.
The cumulative incidence of acute GVHD, grades II-IV and III-
IV were 40% and 13%, respectively, and chronic GVHD was 22%
(7% for extensive). The cumulative incidence of TRM at 100 days
and 1 year were 17% and 33%, respectively. There were 22 deaths:
recurrence 14, infection 4, GVHD 4.
Conclusion: RIC HSCT can provide disease control in patients
with ALL, andmerits further evaluation. Alternative treatment strat-
egies need to be explored in pts with advanced disease. The observed
TRM rate is comparable to previously reported rates in in heavily
pre-treated leukemia patients.170
EPIGENETIC REGULATIONS INFLUENCE CML CELL SENSITIVITY TO
BUSULFAN: RELEVANCE TO PRETRANSPLANT CONDITIONING THERAPY
Valdez, B.C.1, Li, Y.1, Murray, D.2, Champlin, R.E.1, Andersson, B.S.1
1 UT MD Anderson Cancer Center, Houston, TX; 2 Cross Cancer Institute,
Edmonton, AB, Canada
Busulfan (Bu) is a DNA-alkylating drug which is commonly used
in myeloablative pretransplant conditioning therapy in patients with
CML. A major obstacle to successful treatment is inherent or
acquired cellular Bu-resistance. Knowing that DNA hypermethyla-
tion may contribute to drug resistance, we hypothesized that cellular
Bu-resistance can be reversed by altered epigenetic regulation. We
established a Bu-resistant CML cell line B5/Bu2506 which is 4-
fold more resistant to Bu than the parental B5 cells but 4-fold collat-
erally sensitive to 5-aza-2’-deoxycytidine (DAC). Real-time PCR
analysis of the expressions of known DNA methyltransferases
showed upregulation of DNMT3B in B5/Bu2506 cells relative to
the parental B5 cells without significant changes in DNMT1,
DNMT2, and DNMT3A. This result suggests that B5/Bu2506 cells
might be addicted to DNMT3B to epigenetically regulate expres-
sion of genes involved in Bu resistance; exposure to DAC might in-
hibit DNMT3B enzyme and sensitize cells to Bu. Indeed, exposure
to DAC synergistically increased Bu-mediated cytotoxicity in B5/
Bu2506 cells as evaluated by the MTT assay and median-effect anal-
ysis (combination index\ 0.5). The DAC-induced sensitivity to Bu
of B5/Bu2506 cells was associated with PARP1 cleavage, phosphor-
ylation of histone 2A and activation of caspases 3, 8 and 9 suggesting
induction of apoptotic response. Real-time PCR and immunostain-
ing analyses of the expressions of various viability-related genes,
which are known to be epigenetically regulated, showed significant
increase in the expression of CDKN2A (p16INK4A) and XAF1 (X-
linked inhibitor of apoptosis protein (XIAP)-associated factor 1)
genes in B5/Bu2506 cells exposed to DAC. Analyses of their
promoter regions by methylation-specific PCR showed a significant
decrease in their methylation status which correlates with the alter-
ation in their gene expression in the presence of DAC. The
64 Poster Session-Iupregulation of CDKN2A and XAF1 expressions correlate with
downregulation of their downstream target proteins including phos-
phorylated Rb and XIAP, respectively. Based on the present data and
our previously published results, the synergistic effects of DAC and
Bu involve cell cycle arrest and apoptosis induction. Our results sug-
gest that DNA methylation status may be used to identify leukemia
patients who could benefit from Bu-DAC combinations to achieve
improved leukemic cytoreduction with the conditioning program
prior to stem cell transplantation.171
ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) AFTER FIRST RE-
LAPSE IN ADULT PATIENTS WITH ACUTE LYMPHOCYTIC LEUKEMIA
(ALL)
Arnold, R.1, Terwey, T.1, Hemmati, P.1, le Coutre, P.1, Neuburger, S.1,
Dorken, B.1, Massenkeil, G.2, Gokbuget, N.3 1 Charite University Medi-
cine, Berlin, Germany; 2 Klinikum Gu¨tersloh, Guetersloh, NRW,
Germany; 3 Frankfurt University, Frankfurt, Hessen, Germany
70 adult ALL patients (pts) were transplanted after 1. relapse
(leukemic blasts .5% in bone marrow or central nervous system
involvement) in a single center between 1995 and 2007. 2 pts
were excluded from the analysis because diagnosis of ALL was
made in childhood and they were transplanted in adult age. Median
age of the analyzed 68 pts was 28 years (16–54). 43 pts were male,
25 female. 32 pts were transplanted in 1. relapse, 24 pts in CR2 and
12 pts beyond CR2 (.CR2). Stem cell donors were HLA identical
sibling (n 5 24), identical twin (n 5 1), HLA identical child (n 5 1)
and unrelated donors (n 5 42). Standard conditioning was
12GyTBI and cyclophosphamide (CY) or VP16 (myeloablative
conditioning 5 MAC). Pts with comorbidities and contraindica-
tions against MAC received a dose reduced regimen (RIC) with
FLUD, BU and ATG (n 5 3). 18/68 pts (26%) are alive in
CCR, 50/68 pts (74%) are dead. Causes of death were leukemia
in 30/50 and transplant related morbidity, TRM in 20/50 pts
(GvHD and/or infection). For the whole patient group, probability
of survival (prob OS) at 7 years is 0.21 as is disease free survival.
Prob TRM is 0.43. Prob OS regarding stage of disease at SCT
was 0.26 for pts transplanted in 1. relapse, 0.23 for pts transplanted
in CR2 and 0.08 for pts transplanted beyond CR2. Prob OS after
unrelated donor or family donor transplantation was not different
(0.20 vs 0.22). Influence of leukemic risk factors on the prob OS
was analyzed. Risk group at diagnosis and during chemotherapy
(standard vs high risk group, criteria according to the GMALL
Studies) had no significant influence on the prob OS: 0.18 vs
0.25. Pts with B-lineage ALL had a prob OS of 0.25 vs 0.08 in
pts with T-lineage (n. s.). The median duration of 1. remission
for all pts was 9 months (1–72). Prob OS for pts with a remission
duration #9 months or .9 months was 0.24 and 0.17, resp. In con-
clusion, allogeneic SCT can cure ALL pts after 1. clinical relapse.
Our data show a high relapse rate even after standard conditioning
with 12GyTBI. Since conditioning can not be intensified further
because of high TRM, another transplant strategy should be dis-
cussed. Analysis of minimal residual disease (MRD) should be
done regularly during therapy and follow up of ALL pts. If molec-
ular relapse is detected, allogeneic SCT should be performed im-
mediately to avoid therapy refractory clinical relapse. In this
setting 5 pts with MRD positivity were transplanted in CR1 and
4/5 pts are alive in CCR.172
SAFETY AND EFFICACY OF FLUDARABINE AND PK-TARGETED INTRAVE-
NOUS BUSULFAN BEFORE ALLOGRAFTING FOR ADULT ALL
Anasetti, C., Santarone, S., Alsina, M., Ayala, E., Field, T., Kharfan-
Dabaja, M., Ochoa, L., Perez, L., Perkins, J., Raychaudhuri, J.,
Sullivan, D., Fernandez, H. Moffitt Cancer Center, Tampa, FL
Remission consolidation with allogeneic blood or marrow trans-
plantation improves survival of young patients with acute lymphoid
leukemia (ALL), but the potential benefit of transplantation in older
patients is offset by regimen toxicity and non-relapse mortality. Bu-
sulfan is not thought to be an effective drug for ALL, presumably be-
cause of intrinsic resistance of ALL to alkylating agents, or perhapsbecause of the large variability in busulfan pharmacokinetics and er-
ratic drug exposure. Here we report results of treatment with a PK-
targeted intravenous busulfan regimen in 25 adults with ALL. Pa-
tient age was 23–55 (median 40) years, 13 were treated in first com-
plete remission, 10 in second remission, and 2 with resistant disease.
Treatment was with 4 consecutive daily doses of fludarabine 40 mg/
m2, followed by intravenous busulfan, administered on days 1 and 2
at 130–145 mg/m2 daily over 4 hours with PK-sampling and mass
spectrometry assay. On days 3 and 4 busulfan dose was adjusted to
target an average area under the concentration curve of 5300 6
530 mMol*min/L for each of the four days. Donors were siblings
(14), or unrelated (11). Grafts were T-replete, filgrastim-mobilized
hematopoietic blood cells. GVHD prophylaxis was tacrolimus plus
methotrexate or mycophenolate mofetil. Mortality from all non-
relapse causes was 4% at 100 days, and 8% at one year. The one-
year overall survival (OS) was 66%, and relapse-free survival (RFS)
was 62%, with a median follow-up of 1.3 years for live patients.
For patients transplanted in CR1, one-year OS was 77% and RFS
70%; in CR2, OS and RFS were 58%; and with resistant disease,
OS and RFS were 0%. OS was 56% in patients up to 40 years, and
67% in patients 41–55 years old, with disease status and stage simi-
larly distributed in younger and older cohorts. With this treatment
protocol, the one-year non-relapse mortality is identical to what is
observed with non-transplant therapies. When compared to irradia-
tion-containing regimens, fludarabine and PK-targeted busulfan ap-
pear much safer and similarly effective in controlling ALL, providing
a treatment option for all adult patients with ALL. A multicenter
study comparing this transplant protocol against post-remission che-
motherapy for adult ALL is warranted.173
CLOFARABINE-INDUCED REMISSION IN RELAPSED PEDIATRIC ACUTE
MYELOGENOUS LEUKEMIA
Gordon, C., Megason, G., Ledbetter, A. University of Mississippi Medical
Center, Jackson, AZ
Despite improvements, the prognosis for children with recurrent
or progressive acute myeloid leukemia (AML) remains poor; the 5-
year relative survival rate for children under age 15 yrs is 54% (Jemal,
et al.,Ca Cancer J Clin 2008). Early relapse, defined as relapse within
18 months or less from time of initial diagnosis, is associated with
a second CR rate of about 50% and an overall survival of\10%
(Stahnke, K. et al. Leuk 1998). The second generation purine nucle-
oside analog clofarabine was designed to improve on the efficacy and
safety of cladribine and fludarabine. Interest in the utility of clofara-
bine in the treatment of pediatric patients with AML was stimulated
by its Food and Drug Administration approval for the treatment of
pediatric patients with relapsed ALL previously treated with at least
2 regimens. We report on our experience using clofarabine in 6 pe-
diatric patients with relapsed AML, 4 of whom achieved complete re-
mission (CR) with this single agent. All patients received clofarabine
IV at the recommended dose of 52 mg/m2/day for 5 days, with cycles
every 2 to 6 wks depending on count recovery. Patient 1, who never
achieved CR with prior therapies, received clofarabine after she re-
lapsed 6 mos.following a bone marrow transplant (BMT); she
achievedCR after 2 treatment cycles. Despite CR, this severely ill pa-
tient ultimately died with multiple organ failure, pneumonia, and
sepsis. Patient 2 obtained a CR after one cycle of clofarabine and
CR continues after 7 cycles. However, the original plan to maintain
this patient on clofarabine for 1 yr. was not achieved because of
chronic transfusion dependent thrombocytopenia. Patient 3 achieved
a CR after one cycle of clofarabine and received an additional cycle as
maintenance while awaiting BMT. Patient 4 had a CR with one cycle
of clofarabine following a relapse after a first BMT. The patient re-
ceived 2 additional cycles as maintenance before proceeding to a 2nd
BMT. This patient relapsed after the second BMT and is currently
receiving induction with clofarabine. Patients 5 & 6 had not re-
sponded well to previous treatments and failed to respond to a single
cycle of clofarabine. Patient 5 never achieved CR despite gemtuzu-
mab and BMT. Patient 6 had an unsustained CR2 with gemtuzumab
and failed subsequent therapies. Our experience indicates that sin-
gle-agent clofarabine as induction therapy can provide durable
CRs in pediatric patients with relapsed AML and provide a bridge
to subsequent BMT.
